Publikationen in Zusammenarbeit mit Forschern von Novartis (Sweden) (6)

2023

  1. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

    Leukemia, Vol. 37, Núm. 3, pp. 617-626

2022

  1. CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S295-S296

2021

  1. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    Blood, Vol. 138, Núm. 21, pp. 2031-2041

  2. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

    Leukemia, Vol. 35, Núm. 5, pp. 1344-1355

2018

  1. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

    Journal of Cancer Research and Clinical Oncology, Vol. 144, Núm. 5, pp. 945-954

2017

  1. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom study

    Leukemia, Vol. 31, Núm. 7, pp. 1525-1531